At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 35 enrolled
Drug / intervention
LCZ696 +2 moredrug
Likely dose
LCZ696 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-center, Open Label Study for Evaluation of the Safety, Tolerability and Efficacy of 8-week Treatment With LCZ696 in Japanese Patients With Severe Hypertension
In Brief
A Phase 3 clinical trial evaluating LCZ696 for Severe Hypertension. Completed, enrolled 35 participants across 9 sites.
Detailed Summary
This study assessed the safety, tolerability, and efficacy of LCZ696 in severe hypertensive Japanese patients
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSevere Hypertension
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2012
First PostedJul 2012
Primary CompletionFeb 2013
TodayJul 2026
First PostedJul 20, 2012
Enrollment StartJul 1, 2012
Primary CompletionFeb 1, 2013
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 14.0 years ago
Interventions
LCZ696drug
LCZ696 200 mg tablet once daily
LCZ696drug
2 tablets of LCZ696 200 mg once daily titrated up from 1 tablet of 200 mg once daily
LCZ696drug
2 tablets of LCZ696 200 mg once daily titrated up from 1 tablet of 200 mg once daily plus other HTN medications